Wedbush Lowers ITeos Therapeutics' Price Target to $33 From $45 Following Model Update; Keeps Outperform Rating
Wedbush Lowers ITeos Therapeutics' Price Target to $33 From $45 Following Model Update; Keeps Outperform Rating
模型更新后,Wedbush 将iTeos Therapeutics的目标股价从45美元下调至33美元;维持跑赢大盘的评级
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册